Vaccine Containing Virus-Like Particles

Abstract

The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.

1 .- 15 . (canceled) 
     
     
         16 . A method for manufacturing a vaccine containing virus-like particles, comprising:
 fixing particle structures of virus particles having an envelope; and   performing a delipidation treatment on the fixed virus particles.   
     
     
         17 . The manufacturing method according to  claim 16 , wherein the fixing includes adding a fixative to a suspension A containing the virus particles. 
     
     
         18 . The manufacturing method according to  claim 17 , wherein the fixative contains aldehydes. 
     
     
         19 . The manufacturing method according to  claim 17 , wherein the fixative contains 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC). 
     
     
         20 . The manufacturing method according to  claim 18 , wherein the aldehydes are selected from the group consisting of formaldehyde, paraformaldehyde, glutaraldehyde, and a combination of these. 
     
     
         21 . The manufacturing method according to  claim 20 , wherein the aldehydes contain formaldehyde. 
     
     
         22 . The manufacturing method according to  claim 21 , wherein a concentration of the formaldehyde is 0.007 to 0.076 w/v % based on a total amount of the suspension A and the fixative. 
     
     
         23 . The manufacturing method according to  claim 20 , wherein the aldehydes contain glutaraldehyde. 
     
     
         24 . The manufacturing method according to  claim 23 , wherein a concentration of the glutaraldehyde is 0.002 to 0.05 w/v % based on a total amount of the suspension A and the fixative. 
     
     
         25 . The manufacturing method according to  claim 16 , wherein the step of performing a delipidation treatment includes adding a delipidation agent to a suspension B containing the fixed virus particles. 
     
     
         26 . The manufacturing method according to  claim 25 , wherein the delipidation agent is selected from the group consisting of diethyl ether, diisopropyl ether, methyl acetate, ethyl acetate, and a combination of these. 
     
     
         27 . The manufacturing method according to  claim 26 , wherein the delipidation agent contains diethyl ether. 
     
     
         28 . The manufacturing method according to  claim 27 , wherein a concentration of the diethyl ether is equal to or higher than 10 vol % based on a total amount of the suspension B and the delipidation agent. 
     
     
         29 . The manufacturing method according to  claim 25 , wherein the delipidation agent further contains a surfactant. 
     
     
         30 . The manufacturing method according to  claim 16 , wherein the virus particles are recovered after being caused to infect a culture cell or a chicken egg. 
     
     
         31 . The manufacturing method according to  claim 30 , wherein the culture cell is a Vero cell or an MDCK cells.